Transcend Capital Advisors LLC Has $519,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Transcend Capital Advisors LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,619 shares of the biopharmaceutical company's stock after selling 2,787 shares during the quarter. Transcend Capital Advisors LLC's holdings in Gilead Sciences were worth $519,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. First Bank & Trust increased its stake in shares of Gilead Sciences by 0.7% in the fourth quarter. First Bank & Trust now owns 51,929 shares of the biopharmaceutical company's stock valued at $4,797,000 after buying an additional 354 shares during the period. Advyzon Investment Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $418,000. Handelsbanken Fonder AB increased its position in Gilead Sciences by 9.6% during the 4th quarter. Handelsbanken Fonder AB now owns 590,156 shares of the biopharmaceutical company's stock valued at $54,513,000 after purchasing an additional 51,453 shares during the period. Sunpointe LLC increased its position in Gilead Sciences by 12.0% during the 4th quarter. Sunpointe LLC now owns 4,654 shares of the biopharmaceutical company's stock valued at $430,000 after purchasing an additional 500 shares during the period. Finally, Global Retirement Partners LLC increased its position in Gilead Sciences by 2.2% during the 4th quarter. Global Retirement Partners LLC now owns 8,982 shares of the biopharmaceutical company's stock valued at $830,000 after purchasing an additional 194 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the firm's stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares of the company's stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 713,000 shares of company stock worth $67,945,181. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Oppenheimer increased their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Barclays increased their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $102.08.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $109.95 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock's fifty day simple moving average is $95.41 and its two-hundred day simple moving average is $88.73. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $111.03. The stock has a market cap of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. Gilead Sciences's dividend payout ratio (DPR) is 832.43%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.